ACHV: financial statements from SEC — TradeAlmanac

ACHV

Achieve Life Sciences, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Research and development	—	5m	7m	7m	8m	5m
Selling, general and administrative	—	9m	6m	6m	5m	3m
Operating expenses	10m	15m	13m	13m	12m	8m
Interest expense	—	—	—	—	366,000	804,000
Net income	−10m	−14m	−13m	−13m	−13m	−8m
Earnings per share	−0.19	−0.28	−0.37	−0.37	−0.36	−0.25
Earnings per share, diluted	−0.19	−0.28	−0.37	−0.37	−0.36	−0.25
Weighted average shares	53m	51m	35m	35m	34m	34m
Weighted average shares, diluted	53m	51m	35m	35m	34m	34m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	28m	21m	32m	52m	13m	13m	10m	15m
Short-term investments	1m	15m

Cash flow

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Operating cash flow	−7m	—	—	−11m	—	—
Depreciation and amortisation	57,000	—	—

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)